Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: whyretire who wrote (1123)	11/6/1998 9:29:00 AM
From: eRM Solutions	Read Replies (1) \| Respond to of 3576

To All, I don't own any GERN although I wish I did, just wanted to say congratulations! What a gap up. Regards John

To: whyretire who wrote (1123)	11/6/1998 9:30:00 AM
From: BomboochaBoy	Read Replies (1) \| Respond to of 3576

Post-Circus, some numbers show GERN deserves a better stock price than ENMD. If ENMD is at $28 stock, GERN should be 35-50 in comparison to ENMD, based loosely on these limited revenue/loss figures...? Of course, this morning is another story. Straight to the moon, Alice, straight to the moon! (Stocksite #'s) ENMD researches and develops biopharmaceutical products that address the role of blood and blood vessels in the prevention of a broad range of diseases. For the six months ended 6/98, revenues rose 6% to $2.3M. Net loss rose 89% to $4.9M.Results reflect grant revenues earned under a Small Business Innovative Research program from the NIH. Higher loss reflects higher R&D costs due to greater efforts in angiogenesis and cell permeation product development. Price & Volume Recent Price $26.1352 Week High $85.0052 Week Low $6.50 Avg Daily Vol (Mil)0.24 Beta1.51 Share Related Items Mkt. Cap. (Mil) $338.91 Shares Out (Mil)12.97 Float (Mil)8.60 Institutional Holdings (Mil)1.71 Geron is a biopharmaceutical company exclusively focused on discovering and developing therapeutic and diagnostic products based upon common biological mechanisms underlying cancer and other age-related diseases. For the 6 months ended 6/30/98, revenues rose 65% to $3.8M. Net loss fell 31% to $4.3M. Revenues reflect increased research support payments from collaborative aggreements. Lower loss was partially offset higher legal and communication costs. Price & Volume Recent Price $6.19 (*** NOT THE CURRENT PRICE, OF COURSE) 52 Week High $17.1352 Week Low $3.50 Avg Daily Vol (Mil)0.09 Beta0.41 Share Related Items Mkt. Cap. (Mil) $69.64 Shares Out (Mil)11.25 Float (Mil)5.70 Institutional Holdings (Mil)1.46